Skip to content
AnalystLens

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Financial Results (May 5, 2025)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed May 5, 2025
Period End
May 5, 2025
Security
VRTX
In the record · 2016–202610-K1110-Q328-K100

VRTX filed 11 annual reports (10-K), 32 quarterly reports (10-Q) and 100 current reports (8-K) between 2016 and 2026.

  1. Deal closed8-K · Oct ’17Oct ’17
  2. Leadership change8-K · Apr ’20Apr ’20
  3. Material agreement8-K · Jul ’22Jul ’22
  4. Leadership change8-K · Oct ’26Oct ’26

01—Abstract

Summary

Summary of the 8-K filed May 5, 2025. Cited figures are marked; the original filing is the authoritative source.

Vertex Pharmaceuticals reported first-quarter 2025 results with total revenue of $2.77 billiona, up 3% year over year, driven by TRIKAFTA/KAFTRIO (about $2.54 billion) and an early contribution from the U.S. launch of ALYFTREK.

U.S. revenue rose 9% to $1.66 billionb on strong demand and higher net realized pricing, while ex-U.S. revenue fell 5% to $1.11 billion, largely due to the expected revenue decline in Russia, where Vertex cites intellectual property violations. The company raised the low end of its full-year 2025 total revenue guidance by $100 million to $11.85–$12.0 billion, and reiterated its GAAP and non-GAAP expense and non-GAAP tax rate guidance. Profitability was mixed.

GAAP net income fell to $646 millionc (diluted EPS $2.49) from $1.1 billion a year earlier, reflecting a $379.0 million intangible asset impairment tied to VX-264 (the cells-plus-device type 1 diabetes program, now discontinued) and higher operating spend. Non-GAAP net income was $1.1 billion (diluted EPS $4.06), down from $1.2 billion. Combined R&D, acquired IPR&D and SG&A expenses rose on pipeline investment and JOURNAVX commercial launch costs.

Cash and marketable securities were $11.4 billiond at quarter end, up from $11.2 billion, despite ongoing share repurchases. The quarter's pipeline and launch news was substantial. JOURNAVX (suzetrigine), the non-opioid acute pain drug, has broad early uptake with roughly 94 million lives with covered access and a formal agreement with a large PBM.

Povetacicept has completed enrollment of its IgAN interim cohort, with a potential U.S. accelerated approval filing in the first half of 2026, and has moved into pivotal development in primary membranous nephropathy. Zimislecel's Phase 3 dosing is expected to complete in Q2 2025, with filings planned for 2026. Investors should note that the company's guidance is reaffirmed in its essentially unchanged expense outlook, and that the VX-522 MAD study was paused for a tolerability issue.

02—Key points

Key Highlights

  1. Total revenue rose 3% to $2.77 billion; U.S. revenue grew 9% to $1.66 billion while ex-U.S. revenue fell 5% to $1.11 billion on the Russia revenue decline.
  2. FY2025 total revenue guidance raised at the low end by $100 million to $11.85–$12.0 billion.
  3. GAAP net income fell to $646 million (EPS $2.49) from $1.1 billion, driven by a $379.0 million impairment on the discontinued VX-264 program; non-GAAP EPS was $4.06 versus $4.76.
  4. ALYFTREK launched in the U.S. and U.K., contributing $53.9 million in its first partial quarter; CASGEVY contributed $14.2 million.
  5. JOURNAVX has about 94 million lives with covered access and roughly 42 million with unrestricted access, plus a formal agreement with a large national PBM covering about 22 million commercial lives.
  6. Povetacicept IgAN interim cohort is fully enrolled, with potential U.S. accelerated approval filing in 1H 2026; pivotal pMN development is set to begin in 2025.
  7. Cash, cash equivalents and marketable securities reached $11.4 billion, supported by operating cash flow and partly offset by share repurchases.

03—Questions

Frequently Asked Questions

  1. Why did GAAP net income decline so sharply despite revenue growth?

    GAAP net income fell to $646 million from $1.1 billion mainly because of a $379.0 million intangible asset impairment charge related to VX-264, a type 1 diabetes program that is being discontinued, along with higher R&D and SG&A spending. Non-GAAP net income, which excludes these items, declined more modestly to $1.1 billion.

  2. Did Vertex change its full-year 2025 guidance?

    Only partly. Vertex raised the low end of its total revenue guidance by $100 million, to $11.85–$12.0 billion. Its combined GAAP and non-GAAP expense guidance and its non-GAAP effective tax rate guidance (20.5%–21.5%) were unchanged.

  3. How is the JOURNAVX launch progressing?

    Early uptake is encouraging: more than 20,000 prescriptions were written and filled from early March through April 18, roughly 94 million lives have covered access, about 42 million have unrestricted access, and more than 50 large healthcare systems have started formulary reviews. Launch revenue was insignificant in Q1 2025, so near-term financial contribution remains small.

  4. What is the impact of the Russia situation on Vertex's revenue?

    Ex-U.S. revenue declined 5% to $1.11 billion, in part because of an expected revenue decline in Russia, where Vertex says its intellectual property rights are being violated. Management characterizes this as a limited and isolated matter, though the filing does not quantify the Russia revenue at risk.

  5. What are the key pipeline catalysts to watch in 2025 and 2026?

    Key catalysts include completion of zimislecel's pivotal dosing in Q2 2025 with filings planned for 2026, initiation of the povetacicept pMN Phase 2/3 study, completion of enrollment in the inaxaplin AMPLITUDE interim cohort in 2H 2025, VX-993 Phase 2 results in 2H 2025, and a potential povetacicept IgAN accelerated approval filing in 1H 2026.

04—Continue

← View all 8-K filings